Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS

被引：0
|
作者：
Lipton, R. B. [1 ]
Chalermpalanupap, N. [2 ]
Tatsuoka, Y. [3 ]
Nagy, K. [4 ]
Liu, Y. [5 ]
Carr, K. [5 ]
McAllister, P. [6 ]
Nahas, S. J. [7 ]
Trugman, J. M. [2 ]
Sacco, S. [8 ]
机构：
[1] Albert Einstein Coll Med, Bronx, MA USA
[2] AbbVie, Madison, NJ USA
[3] Tatsuoka Neurol Clin, Kyoto, Japan
[4] AbbVie, Budapest, Hungary
[5] AbbVie, N Chicago, IL USA
[6] New England Inst Neurol & Headache, Stamford, CT USA
[7] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[8] Univ Aquila, Laquila, Italy
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P036
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, Patricia
    Ailani, Jessica
    Ashina, Messoud
    Goadsby, Peter J.
    Lipton, Richard
    Reuter, Uwe
    Guo, Hua
    Schwefel, Brittany
    Boinpally, Ramesh
    McCusker, Emily
    Yu, Sung Yun
    Finnegan, Michelle
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 14 - 15
  • [22] Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
    Goadsby, Peter J.
    Dodick, David W.
    Martinez, James M.
    Ferguson, Margaret B.
    Oakes, Tina M.
    Zhang, Qi
    Skljarevski, Vladimir
    Aurora, Sheena K.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (08): : 939 - 944
  • [23] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, Patricia
    Ailani, Jessica
    Ashina, Messoud
    Goadsby, Peter
    Lipton, Richard
    Reuter, Uwe
    Guo, Hua
    Schwefel, Brittany
    Boinpally, Ramesh
    McCusker, Emily
    Yu, Sung Yun
    Finnegan, Michelle
    Trugman, Joel
    NEUROLOGY, 2023, 100 (17)
  • [24] Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
    Pazdera, Ladislav
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Yang, Ronghua
    Pozo-Rosich, Patricia
    CEPHALALGIA, 2021, 41 (10) : 1075 - 1088
  • [25] 10-year cost-effectiveness analyses of fremanezumab compared to erenumab as preventive treatment in episodic migraine for patients with inadequate response to prior preventive treatments
    Smolen, Lee
    Cohen, Joshua M.
    Klein, Timothy
    Gandhi, Sanjay K.
    Thompson, Stephen
    CEPHALALGIA, 2019, 39 (1_SUPPL) : 405 - 405
  • [26] 10-Year Cost-effectiveness Analyses of Fremanezumab Compared to Erenumab as Preventive Treatment in Episodic Migraine for Patients With Inadequate Response to Prior Preventive Treatments
    Smolen, Lee
    Cohen, Joshua
    Klein, Timothy
    Gandhi, Sanjay K.
    Thompson, Stephen
    NEUROLOGY, 2020, 94 (15)
  • [27] 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO ERENUMAB AS PREVENTIVE TREATMENT IN EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS
    Smolen, L.
    Cohen, J.
    Klein, T.
    Gandhi, S. K.
    Thompson, S.
    VALUE IN HEALTH, 2019, 22 : S743 - S743
  • [28] Sustained, clinically meaningful responses to fremanezumab treatment in migraine patients with inadequate response to 2-4 prior classes of migraine preventive medications
    Dougherty, C. O.
    Cohen, J. M.
    Campos, Ramirez, V
    Ning, X.
    Barash, S.
    Spierings, E. L. H.
    HEADACHE, 2021, 61 : 147 - 147
  • [29] Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
    Lipton, Richard B.
    Nahas, Stephanie J.
    Pozo-Rosich, Patricia
    Bilchik, Tanya
    McAllister, Peter
    Finnegan, Michelle
    Liu, Yingyi
    Chalermpalanupap, Natty
    Dabruzzo, Brett
    Dodick, David W.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [30] Response Rates With Oral Atogepant in Participants With Prior Preventive Treatment Failure: Results From ELEVATE
    Pozo-Rosich, P.
    Nagy, K.
    Tassorelli, C.
    Lanteri-Minet, M.
    Sacco, S.
    Nezadal, T.
    Finnegan, M.
    Luo, L.
    Gandhi, P.
    Trugman, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 213 - 214
12345